• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

精神科门诊广泛性焦虑障碍患者的残疾和与健康相关的生活质量:是否仍有改进的空间?

Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: is there still room for improvement?

机构信息

Psychiatry Department - Oviedo University, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Oviedo, Asturias, Spain.

出版信息

Ann Gen Psychiatry. 2011 Mar 14;10(1):7. doi: 10.1186/1744-859X-10-7.

DOI:10.1186/1744-859X-10-7
PMID:21401940
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3064614/
Abstract

OBJECTIVE

We assessed the impact of generalised anxiety disorder (GAD) on disability and health-related quality of life in outpatients treated in psychiatric clinics via a secondary analysis conducted in 799 patients from a cross-sectional study of prevalence of GAD in psychiatric clinics.

METHODS

Patients were allocated into two groups: follow-up (15.7%) and newly diagnosed patients (84.3%), and were administered the Hamilton Anxiety Scale (HAM-A), Clinical Global Impressions Scale (CGI), Sheehan Disability Scale (SDS), and 36-item short form structured quality of life questionnaire (SF-36) scales.

RESULTS

The newly diagnosed group showed higher significant intensity of anxiety (56.9% vs 43.0% (HAM-A >24)), psychiatrist's CGI Severity (CGI-S) scores (4.2 vs 3.7), and perceived stress according to SDS (5.7 vs 5.2). They also showed lower scores in mental health-related quality of life: 25.4 vs 30.8. Statistical differences by gender were not observed. GAD was shown to have a significant impact on patient quality of life and disability, with a substantial portion having persistent, out of control symptoms despite treatment.

CONCLUSIONS

These results suggest that there is still room for improvement in the medical management of patients with GAD treated in psychiatric clinics.

摘要

目的

通过对精神科诊所广泛性焦虑障碍(GAD)患病率横断面研究中的 799 例患者进行二次分析,评估广泛性焦虑障碍对精神科诊所门诊患者残疾和健康相关生活质量的影响。

方法

将患者分为两组:随访组(15.7%)和新诊断组(84.3%),并对其进行汉密尔顿焦虑量表(HAM-A)、临床总体印象量表(CGI)、Sheehan 残疾量表(SDS)和 36 项简明健康状况调查问卷(SF-36)评分。

结果

新诊断组焦虑严重程度较高(56.9%比 43.0%(HAM-A>24))、精神病医生 CGI 严重程度评分(CGI-S)较高(4.2 比 3.7)、SDS 感知压力较高(5.7 比 5.2)。他们的心理健康相关生活质量评分也较低:25.4 比 30.8。性别差异无统计学意义。GAD 显著影响患者的生活质量和残疾,尽管接受了治疗,但仍有相当一部分患者存在持续、失控的症状。

结论

这些结果表明,精神科诊所治疗的 GAD 患者的医疗管理仍有改进空间。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b3f/3064614/00fd7639c75c/1744-859X-10-7-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b3f/3064614/00fd7639c75c/1744-859X-10-7-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b3f/3064614/00fd7639c75c/1744-859X-10-7-1.jpg

相似文献

1
Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: is there still room for improvement?精神科门诊广泛性焦虑障碍患者的残疾和与健康相关的生活质量:是否仍有改进的空间?
Ann Gen Psychiatry. 2011 Mar 14;10(1):7. doi: 10.1186/1744-859X-10-7.
2
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.文拉法辛缓释胶囊治疗非抑郁广泛性焦虑障碍门诊患者的疗效:一项为期6个月的随机对照试验。
JAMA. 2000 Jun 21;283(23):3082-8. doi: 10.1001/jama.283.23.3082.
3
Implications of pain in generalized anxiety disorder: efficacy of duloxetine.广泛性焦虑症中疼痛的影响:度洛西汀的疗效
Prim Care Companion J Clin Psychiatry. 2008;10(3):197-204. doi: 10.4088/pcc.v10n0304.
4
Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.文拉法辛缓释剂用于多躯体形式障碍的抑郁和焦虑初级护理患者的短期治疗。
J Clin Psychiatry. 2006 Jan;67(1):72-80. doi: 10.4088/jcp.v67n0111.
5
Health-related quality of life and utilities in primary-care patients with generalized anxiety disorder.广泛性焦虑症初级保健患者的健康相关生活质量及效用值
Qual Life Res. 2008 Dec;17(10):1285-94. doi: 10.1007/s11136-008-9406-6. Epub 2008 Oct 23.
6
Cardiac autonomic tone, plasma BDNF levels and paroxetine response in newly diagnosed patients of generalised anxiety disorder.广泛性焦虑障碍初诊患者的心脏自主神经张力、血浆脑源性神经营养因子水平和帕罗西汀反应。
Int J Psychiatry Clin Pract. 2020 Jun;24(2):135-142. doi: 10.1080/13651501.2020.1723642. Epub 2020 Feb 5.
7
Burden of illness and health care resource utilization in adult psychiatric outpatients with attention-deficit/hyperactivity disorder in Europe.欧洲成人注意力缺陷多动障碍门诊患者的疾病负担与医疗资源利用情况
Curr Med Res Opin. 2016 Sep;32(9):1547-56. doi: 10.1080/03007995.2016.1189892. Epub 2016 Jun 16.
8
Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.帕罗西汀治疗广泛性焦虑症:一项安慰剂对照、灵活剂量试验的结果。
J Clin Psychiatry. 2001 May;62(5):350-7. doi: 10.4088/jcp.v62n0508.
9
Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.低剂量帕罗西汀控释剂治疗重度抑郁症的疗效
J Clin Psychiatry. 2004 Oct;65(10):1356-64. doi: 10.4088/jcp.v65n1010.
10
Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.使用 Sheehan 残疾量表的 discan 度量评估重度抑郁症和广泛性焦虑症临床试验中的缓解情况。
Int Clin Psychopharmacol. 2011 Mar;26(2):75-83. doi: 10.1097/YIC.0b013e328341bb5f.

引用本文的文献

1
Interpersonal Problems, Mindfulness, and Therapy Outcome in an Acceptance-Based Behavior Therapy for Generalized Anxiety Disorder.广泛性焦虑症的基于接纳的行为疗法中的人际问题、正念与治疗结果
Cogn Behav Ther. 2015;44(6):491-501. doi: 10.1080/16506073.2015.1060255. Epub 2015 Jul 31.
2
Association of comorbid generalized anxiety disorder and alcohol use disorder symptoms with health-related quality of life: results from the National Epidemiological Survey on Alcohol and Related Conditions.共病广泛性焦虑障碍和酒精使用障碍症状与健康相关生活质量的关联:来自全国酒精相关情况的流行病学调查的结果。
J Addict Med. 2013 Nov-Dec;7(6):394-400. doi: 10.1097/ADM.0b013e31829faa1c.
3

本文引用的文献

1
[Clinical prevalence and reason for visit of patients with generalized anxiety disorder seen in the psychiatry out-patient clinics in Spain. Results of the LIGANDO study].
Actas Esp Psiquiatr. 2009 Jan-Feb;37(1):17-20.
2
Relationships among pain, anxiety, and depression in primary care.初级保健中疼痛、焦虑和抑郁之间的关系。
Depress Anxiety. 2008;25(7):593-600. doi: 10.1002/da.20342.
3
Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials.苯二氮䓬类药物治疗广泛性焦虑障碍:基于临床试验系统评价和荟萃分析的结果异质性
Comparison of the course of substance use disorders among individuals with and without generalized anxiety disorder in a nationally representative sample.
在全国代表性样本中,比较有和没有广泛性焦虑障碍的个体的物质使用障碍病程。
J Psychiatr Res. 2012 May;46(5):659-66. doi: 10.1016/j.jpsychires.2012.02.011. Epub 2012 Mar 23.
J Psychopharmacol. 2007 Sep;21(7):774-82. doi: 10.1177/0269881107077355.
4
Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial.广泛性焦虑症患者的健康相关生活质量(HRQOL):在艾司西酞普兰预防复发试验中进行的评估
Curr Med Res Opin. 2007 Oct;23(10):2543-9. doi: 10.1185/030079907X226087.
5
[Pharmacological treatment of generalized anxiety disorders: rationale and limitations].[广泛性焦虑症的药物治疗:基本原理与局限性]
Encephale. 2007 Jan-Feb;33(1):84-94. doi: 10.1016/s0013-7006(07)91562-6.
6
Cognitive impairment in late-life generalized anxiety disorder.老年广泛性焦虑障碍中的认知障碍
Am J Geriatr Psychiatry. 2007 Aug;15(8):673-9. doi: 10.1097/JGP.0b013e31803111f2. Epub 2007 Apr 10.
7
Impact of psychiatric disorders on health-related quality of life: general population survey.精神障碍对健康相关生活质量的影响:普通人群调查
Br J Psychiatry. 2007 Apr;190:326-32. doi: 10.1192/bjp.bp.106.025106.
8
Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection.基层医疗中的焦虑症:患病率、损害、共病情况及检测
Ann Intern Med. 2007 Mar 6;146(5):317-25. doi: 10.7326/0003-4819-146-5-200703060-00004.
9
Generalised anxiety disorder.广泛性焦虑障碍
Lancet. 2006 Dec 16;368(9553):2156-66. doi: 10.1016/S0140-6736(06)69865-6.
10
Insomnia comorbidity and impact and hypnotic use by age group in a national survey population aged 16 to 74 years.在一项针对16至74岁全国调查人群的研究中,失眠共病情况、影响及不同年龄组的催眠药物使用情况。
Sleep. 2006 Nov;29(11):1391-7. doi: 10.1093/sleep/29.11.1391.